BioCorRx (BICX) Akcija Cena

BioCorRx Cena

OTC·SLĒGTS
0,22
​
Tirgus ir slēgts

Pēdējos 15 gados BioCorRx ieņēmumi auga par 12,3 % gadā un sasniedza 797 244,00 USD. BioCorRx neto marža -431,5 % ir pieaugusi salīdzinājumā ar -10 789,4 % pirms dažiem gadiem.

BioCorRx akcijas cena

Iegūstiet šos datus caur Eulerpool API

100 000 pieprasījumu/mēn. bez maksas · bez kartes

BioCorRx biznesa modelis un akciju analīze

Uzņēmums BioCorRx Inc ir ASV uzņēmums, kas dibināts 2008. gadā un kura galvenais birojs atrodas Anaheimā, Kalifornijā. „BioCorRx” specializējas inovatīvu ārstēšanas metožu izstrādāšanā un tirgus veidošanā alkoholismam un narkomānijai. „BioCorRx” vēsture sākās ar tā vadošā produkta – „BioCorRx Recovery Program” – ieviešanu, kas balstās uz jaunu medicīnisko tehnoloģiju – Naltrexone/Buprenorphine Implant. Atšķirībā no tradicionālajām alkoholisma un narkomānijas ārstēšanas metodēm, kas parasti balstās uz zāļu terapiju un psihoterapeitisku atbalstu, „BioCorRx Recovery Program” ir implantējama ilgtermiņa ārstēšanas sistēma, kas nepārtraukti piegādā aktīvo vielu Naltrexone vai Buprenorphine pacienta organismā. Šīs pieejas mērķis ir novērst abstinences simptomus un tādējādi samazināt recidīva risku. Pēdējos gados „BioCorRx” ir paplašinājusi savu produktu portfelī un biznesa darbības jomas jaunās segmentos, lai turpinātu uzņēmuma izaugsmi. Tas ietver, piemēram, telemedicīnas pakalpojumu jomu, kas ļauj „BioCorRx” piedāvāt savas ārstēšanas tehnoloģijas un medicīniskos pakalpojumus, izmantojot tiešsaistes saziņu. Telemedicīnas pakalpojumi, piemēram, virtuālas pacientu konsultācijas vai tiešsaistes grupu terapijas programmas, īpaši ir pieprasīti COVID-19 pandēmijas laikā. Cits „BioCorRx” uzmanības centrs ir medicīniskā personāla pārvaldība. Pētījumi ir parādījuši, ka laba pacientu aprūpe un konsultācijas būtiski ietekmē ārstēšanas panākumus. „BioCorRx” ir izstrādājusi arī savu platformu, kas atvieglo un uzlabo medicīniskā personāla pārvaldību, apmācību un uzraudzību. „BioCorRx” arī izmanto franšīzes sistēmas koncepciju, lai tirgotu savus produktus un pakalpojumus. Franšīzes sistēma piedāvā medicīnas profesionāļiem un organizācijām, kas strādā atkarības ārstēšanas jomā, iespēju atvērt savu „BioCorRx” klīniku un piedāvāt uzņēmuma produktus un pakalpojumus vietējā tirgū. Katru klīniku konsultē un atbalsta „BioCorRx”, un tai ir jāievēro noteikti standarti un kvalitātes kritēriji. Nākotnē „BioCorRx” plāno tālāk diversificēt savu produktu piedāvājumu un izstrādāt jaunās tehnoloģijas, lai uzlabotu ārstēšanas iespējas cilvēkiem ar alkoholismu un narkomāniju. Šādu tehnoloģiju piemērs ir zāles, kas balstītas uz Ibogaine. „BioCorRx” jau ir sākusies sākotnējo pētījumu šajā virzienā un aktīvi strādā pie priekškliniskajiem pētījumiem. Kopumā „BioCorRx” ir uzņēmums, kas galvenokārt koncentrējas uz inovatīvām tehnoloģijām atkarības ārstēšanai. Uzņēmums ir pieredzējis ievērojamu izaugsmi pēdējos gados, paplašinot savu produktu klāstu un klientu bāzi, kā arī fokusējoties uz telemedicīnas, personāla pārvaldības un franšīzes sistēmu jomām. Ar savu perspektīvajām tehnoloģijām un spēcīgu uzsvaru uz kvalitāti un pacientu apmierinātību, tiek prognozēts, ka „BioCorRx” turpinās spēlēt svarīgu lomu atkarības ārstēšanā nākamajos gados.

Bieži uzdotie jautājumi par BioCorRx akciju

The business model of BioCorRx Inc revolves around providing innovative solutions for the treatment of substance abuse and addiction. The company specializes in developing and commercializing behavioral healthcare products and services. BioCorRx Inc offers the BioCorRx Recovery Program, which combines medication-assisted treatment with counseling and peer support. This comprehensive approach aims to help individuals overcome substance abuse by addressing the underlying factors contributing to addiction and promoting long-term recovery. By integrating medical and behavioral components, BioCorRx Inc strives to provide effective solutions for patients seeking to break free from addiction.

BioCorRx Inc is primarily active in the healthcare and pharmaceutical industries.

The main competitors of BioCorRx Inc in the market include pharmaceutical companies, such as Pfizer Inc, Johnson & Johnson, and Novartis AG. Other competitors in the addiction treatment industry include Alkermes plc and Indivior Inc. These companies operate in the same market, offering various products and services for addiction treatment. BioCorRx Inc, a leader in medication-assisted treatment solutions, competes with these companies through its innovative treatment program, BioCorRx Recovery.

BioCorRx Inc is a pharmaceutical company specializing in innovative addiction treatment solutions. Established in 2008, BioCorRx is dedicated to developing effective medications and programs to support those struggling with alcohol and opioid dependencies. The company focuses on combining its proprietary medication, known as the BioCorRx® Recovery Program, with cognitive-behavioral therapy to enhance patient outcomes and reduce relapse rates. With a mission to improve the lives of individuals battling addiction, BioCorRx Inc strives to provide comprehensive and personalized treatment options. Through its commitment and innovative approach, BioCorRx Inc has positioned itself as a leading player in the addiction treatment industry.

BioCorRx Inc, a leading pharmaceutical company, has accomplished several significant milestones in recent years. One of their key achievements includes the development and commercialization of their flagship product, the BioCorRx Recovery Program, which offers a unique, non-addictive approach to treating substance abuse. The company has also made remarkable strides in expanding their distribution networks, forging partnerships with healthcare professionals, and achieving regulatory approvals for their innovative products. Moreover, BioCorRx Inc has consistently demonstrated a commitment to research and development, continually exploring new avenues for improving addiction treatment. These accomplishments highlight BioCorRx Inc's dedication to revolutionizing the field of substance abuse recovery.

BioCorRx Inc is primarily present in the United States. Recognized as a leader in substance use disorder treatment, BioCorRx operates its headquarters in Anaheim, California. With a focus on developing innovative solutions for addiction recovery, the company's presence spans the entire US territory. BioCorRx Inc is dedicated to helping individuals overcome addiction and promoting healthier lives.

BioCorRx Inc represents a strong set of values and a dedicated corporate philosophy. The company is committed to providing innovative solutions in the field of substance use disorder treatment. BioCorRx focuses on developing safe and effective approaches to help individuals overcome addiction and reclaim their lives. With a patient-centric approach, the company aims to provide comprehensive programs that combine medication-assisted treatment with behavioral support. BioCorRx exemplifies integrity, compassion, and a commitment to improving the well-being of individuals struggling with addiction. Through their cutting-edge solutions, BioCorRx Inc strives to make a positive impact in the field of addiction treatment and contribute to the overall betterment of society.

Pēc pašreizējā kursa BioCorRx akcija maksā 0,20 EUR (0,22 USD).

BioCorRx Inc is a leading biotechnology company that develops innovative health solutions for the treatment of addiction disorders. The company specializes in the development and sale of medications for the treatment of drug and alcohol addiction. The company has two different divisions: BioCorRx Pharmaceuticals and BioCorRx Health. BioCorRx Pharmaceuticals focuses on the research, development, and marketing of naltrexone micro-implants for use in alcohol and opioid addiction. These micro-implants are small, biocompatible pellets that are implanted under the skin to allow for continuous release of naltrexone, reducing withdrawal symptoms. BioCorRx Pharmaceuticals also holds a license for the development of buprenorphine implants for the treatment of opioid addiction. The second division, BioCorRx Health, offers a unique integrative health solution for the treatment of addiction disorders. This program includes a variety of services, including program guidance, phone support, online courses, nutritional counseling, exercise therapy, and acupuncture. The program is based on the BioCorRx Recovery Formula, a patented approach that is truly personalized to the patient and their needs. In addition, BioCorRx Inc offers a range of additional products that help reduce addictive behavior and enhance the success of the program. These include capsules for support during withdrawal, special supplements for patients with N-acetylcysteine deficiency, and enhanced vitamin and mineral supplements. BioCorRx Inc has established a strong presence in the US market and is expanding its global presence. The company has formed strategic partnerships with distribution partners to market its products and services worldwide. BioCorRx has also built excellent relationships with addiction researchers, medical professionals, and leading addiction treatment centers. The business model of BioCorRx Inc is based on two pillars: the marketing of patented medications for the treatment of addiction disorders and the sale of integrative health solutions. The company aims to offer a complete, integrated program for the treatment of addiction disorders, which includes both pharmacological treatments and supportive services. Due to the high demand for effective addiction treatments and the high demand for innovative solutions, BioCorRx Inc's business is promising. The company is well positioned to continue growing and dominate the addiction treatment market. The translation is as follows: BioCorRx Inc is a leading biotechnology company that develops innovative health solutions for the treatment of addiction disorders. The company specializes in developing and selling medications to treat drug and alcohol addiction. The company has two divisions: BioCorRx Pharmaceuticals and BioCorRx Health. BioCorRx Pharmaceuticals focuses on researching, developing, and marketing naltrexone micro-implants for alcohol and opioid addiction. These micro-implants are small, biocompatible pellets implanted under the skin to release naltrexone continuously and reduce withdrawal symptoms. BioCorRx Pharmaceuticals also holds a license to develop buprenorphine implants for opioid addiction. BioCorRx Health offers a unique integrative health solution for addiction treatment, including program guidance, phone support, online courses, nutrition counseling, exercise therapy, and acupuncture. The program is based on the BioCorRx Recovery Formula, a patented approach tailored to each patient's needs. Additionally, BioCorRx Inc provides products to reduce addictive behavior and enhance program success. These include withdrawal support capsules, special supplements for N-acetylcysteine deficiency, and improved vitamin and mineral supplements. With a strong presence in the US market and plans for global expansion, BioCorRx Inc has formed strategic partnerships to market its products and services worldwide. The company has also established relationships with addiction researchers, medical professionals, and leading addiction treatment centers. BioCorRx Inc's business model focuses on marketing patented addiction medications and selling integrative health solutions. The company strives to offer a comprehensive program that combines pharmaceutical treatments with supportive services. Given the high demand for effective addiction treatments and innovative solutions, BioCorRx Inc is well positioned for growth and market dominance in addiction treatment.

gaidāmā apgrozījums BioCorRx ir 971 850,00 USD. Šis skaitlis ir balstīts uz pašreizējiem finanšu datiem un atspoguļo uzņēmuma biznesa sniegumu.

gaidāmā peļņa BioCorRx ir -2,20 M USD. Neto peļņa atspoguļo uzņēmuma rentabilitāti pēc visu izdevumu atskaitīšanas.

BioCorRx cenas un peļņas rādītājs (P/E) pašlaik ir -2,45. P/E rādītājs salīdzina pašreizējo akcijas cenu ar peļņu uz akciju un palīdz ieguldītājiem novērtēt BioCorRx akcijas vērtību.

BioCorRx cenas un apgrozījuma rādītājs (P/S) pašlaik ir 5,54. P/S rādītājs salīdzina tirgus kapitalizāciju ar gada apgrozījumu un kalpo kā BioCorRx akcijas vērtības mērs.

BioCorRx Eulerpool kvalitātes rādītājs ir 7/10.

BioCorRx ISIN ir US09073C2052. ISIN (International Securities Identification Number) ir pasaulē unikāls vērtspapīru identifikators.

BioCorRx WKN ir A1XERB. WKN (Wertpapierkennnummer) ir sešciparu vācu vērtspapīru identifikācijas numurs.

BioCorRx tikeris ir BICX. Tikeris tiek izmantots BioCorRx akciju tirdzniecībai biržā.

Taisnīgā vērtībaTerminal
0,18 USD
Pārvērtējums/PasvērtējumsTerminal
Taisnīgi novērtēta
Nozare
Industrija
Veselības aprūpes pakalpojumu sniedzēji un pakalpojumi
Akciju skaits
Darbinieki
Ieņēmumi uz darbinieku
159 448,80 USD
Ieņēmumu pieaugums Ø5 gadi
EBIT pieaugums Ø5 gadi
Neto ienākumu pieaugums Ø5 gadi
Tīmekļa vietne biocorrx.com
Valūta
USD
Publiskais piedāvājums
2010. g. 31. aug.
ISIN
US09073C2052
CUSIP
09073C205
SEDOL
BGLSV90
Tirgus kapitalizācija
2,30 M USDMicro Cap
52 nedēļu diapazons
AAQS
7 / 10
PEG
—
P/E koeficients
P/Ee 2026
-2,45
P/Ee 2027
-2,80
P/S
P/Se
5,54
EV/EBIT
—
P/B attiecība
7,52
ROE (Kapitāla atdeve)
ROA (Aktīvu atdeve)
ROCE (Izmantotā kapitāla atdeve)
ROIC (Ieguldītā kapitāla atdeve)
30,84 %
Pēdējoreiz atjaunināts 2026. g. 3. nov. 16:44

BioCorRx Biržas kods

OTC · BICXOTC · BICX

BioCorRx FIGI

BICX:US · BBG000Q34T88BICX:PQ · BBG000Q34Z48BICX:UV · BBG000Q351D2

Visi BioCorRx fundamentālie rādītāji un padziļinātā analīze

Mūsu akciju analīze par BioCorRx ietver svarīgus finanšu rādītājus, piemēram, apgrozījumu, peļņu, P/E rādītāju, P/S rādītāju, EBIT, kā arī informāciju par dividendēm. Turklāt mēs aplūkojam aspektus kā akcijas, tirgus kapitalizāciju, parādus, pašu kapitālu un saistības no BioCorRx. Ja meklējat sīkāku informāciju par šīm tēmām, piedāvājam detalizētas analīzes mūsu apakšlapās: